Skip to main content

Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer

  • Chapter
  • First Online:
Targeting the DNA Damage Response for Cancer Therapy

Part of the book series: Cancer Treatment and Research ((CTAR,volume 186))

  • 600 Accesses

Abstract

The use of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of patients with germline BRCA mutations (gBRCAm) and breast cancer, both in the early and advanced settings, is a success of genomically-directed treatment. These agents have been shown to be associated with longer progression-free survival when compared to standard chemotherapy, with an acceptable toxicity profile. A recent randomized trial demonstrated improved survival with the use of olaparib for 2 years compared to placebo in patients with early-stage high risk gBRCAm associated breast cancer. Ongoing research efforts are focused on identifying patients beyond those with BRCA1/2 or PALB2 mutations who may benefit from PARP inhibitors, exploring the overlapping mechanisms of resistance between platinum and PARP inhibitors and developing agents with less toxicity that will allow combinational strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Couch FJ, Nathanson KL, Offit K (2014) Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 343:1466–1470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913–917

    Article  CAS  PubMed  Google Scholar 

  3. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921

    Article  CAS  PubMed  Google Scholar 

  4. O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205–214

    Article  CAS  PubMed  Google Scholar 

  5. O’Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M et al (2014) Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32:3840–3847

    Article  CAS  PubMed  Google Scholar 

  6. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH (2012) Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 18:1655–1662

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL (2012) Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 134:649–659

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N et al (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 377:523–533

    Article  CAS  PubMed  Google Scholar 

  9. Robson ME, Im SA, Senkus E, Xu B, Domchek SM, Masuda N et al (2023) OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer 184:39–47

    Article  CAS  PubMed  Google Scholar 

  10. Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM et al (2019) Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. Eur J Cancer 120:20–30

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH et al (2018) Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 379:753–763

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Goncalves A et al (2018) Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol 29:1939–1947

    Article  CAS  PubMed  Google Scholar 

  13. Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Goncalves A et al (2020) Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol 31:1526–1535

    Article  CAS  PubMed  Google Scholar 

  14. Dieras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:1269–1282

    Article  CAS  PubMed  Google Scholar 

  15. Telli ML (2020) BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer? Lancet Oncol 21:1254–1255

    Article  CAS  PubMed  Google Scholar 

  16. Tung N, Garber JE (2022) PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer. 8:47

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A et al (2020) Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol 21:1155–1164

    Article  CAS  PubMed  Google Scholar 

  18. Vinayak S, Tolaney SM, Schwartzberg L, Mita M, McCann G, Tan AR et al (2019) Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol 5:1132–1140

    Article  PubMed  PubMed Central  Google Scholar 

  19. Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G et al (2023) Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b. Tumor-Agnostic Trial. JAMA Oncol. 9:29–39

    Article  PubMed  Google Scholar 

  20. Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR et al (2017) A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer. 3:49

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S et al (2020) Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol 38:388–394

    Article  CAS  PubMed  Google Scholar 

  22. Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA et al (2021) Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study [abstract]. J Clin Oncol 39:505

    Article  Google Scholar 

  23. Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA et al (2022) Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat Cancer. 3:927–931

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 384:2394–2405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L et al (2022) Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol 33:1250–1268

    Article  CAS  PubMed  Google Scholar 

  26. Vliek S, Jager A, Jonge-Lavrencic M, Lotz JP, Goncalves A, Graeser M, et al. Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial [abstract]. Cancer Res. 2018;78:OT2–07–8.

    Google Scholar 

  27. Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK et al (2020) TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol 38:4274–4282

    Article  CAS  PubMed  Google Scholar 

  28. Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN et al (2022) A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat Cancer. 3:1181–1191

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sammons SL, Tan TJ, Im Y-H, Traina T, Anders C, Renzulli E, et al. PD11–12 DORA: A Phase II, Multicenter, International, Non-Comparator Study of Olaparib (O) +/- Durvalumab (D) as a chemotherapy-free maintenance strategy in Platinum tReated Advanced Triple-Negative Breast Cancer (aTNBC) [abstract]. Cancer Res. 2023;83:PD11–2.

    Google Scholar 

  30. Loibl S, O’Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD et al (2018) Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 19:497–509

    Article  CAS  PubMed  Google Scholar 

  31. Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O’Shaughnessy J et al (2022) Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol 33:384–394

    Article  CAS  PubMed  Google Scholar 

  32. Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P et al (2021) Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol 32:49–57

    Article  CAS  PubMed  Google Scholar 

  33. Fasching PA, Schmatloch S, Hauke J, Rey J, Jackisch C, Klare P, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study [abstract]. Cancer Res. 2023;83:P4–06–13.

    Google Scholar 

  34. Michmerhuizen AR, Pesch AM, Moubadder L, Chandler BC, Wilder-Romans K, Cameron M et al (2019) PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. Mol Cancer Ther 18:2063–2073

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Conflicts of Interest

FL reports research grants and personal fees from AstraZeneca, personal fees from Pfizer and Daiichi Sankyo, and research grants from CytomX, Eisai and Incyte. MR reports personal fees for advisory/consulting roles from Artios Pharma Limited, Change Healthcare Inc., Clinical Education Alliance, LLC, Foundation Medicine, Genome Quebec, MJH Associates, myMedEd, Inc., Pfizer, Inc., Tempus Labs, Inc, and Zenith Pharmaceuticals; travel reimbursement and editorial services from AstraZeneca; and research funding from Merck, Pfizer, and AstraZeneca.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Filipa Lynce .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lynce, F., Robson, M. (2023). Clinical Use of PARP Inhibitors in BRCA Mutant and Non-BRCA Mutant Breast Cancer. In: Yap, T.A., Shapiro, G.I. (eds) Targeting the DNA Damage Response for Cancer Therapy. Cancer Treatment and Research, vol 186. Springer, Cham. https://doi.org/10.1007/978-3-031-30065-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-30065-3_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-30064-6

  • Online ISBN: 978-3-031-30065-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics